Metoprolol tartrate extended release pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Pharmacokinetics of Metoprolol Tartrate Extended Release Tablets
Extended Release Formulation and Drug Release Kinetics
Metoprolol tartrate extended release (ER) tablets are designed to provide a controlled and sustained release of the drug over several hours, improving blood pressure control and patient compliance by reducing dosing frequency . The release kinetics of these tablets are often governed by hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), with the drug release mechanism predominantly following Fickian diffusion . Studies show that the release rate and extent of metoprolol absorption are closely related to the in vitro dissolution rate, and the release profile can be tailored by adjusting the polymer content and tablet formulation 264.
Bioavailability and Absorption Profile
The pharmacokinetic profile of metoprolol tartrate ER tablets demonstrates a slower and more prolonged absorption compared to immediate-release formulations. After oral administration, the maximum plasma concentration (Cmax) is lower, and the time to reach Cmax (Tmax) is significantly extended, reflecting the sustained-release nature of the formulation . The mean residence time (MRT) is also prolonged, indicating a longer duration of drug presence in the bloodstream . The relative bioavailability of ER tablets is generally high and comparable between different brands, with studies showing bioequivalence between test and reference products .
Impact of Formulation Variables on Pharmacokinetics
Critical formulation variables such as polymer level, filler ratio, and compression force significantly influence the drug release rate and, consequently, the pharmacokinetics of metoprolol tartrate ER tablets . Increasing the polymer content slows drug release, while changes in excipient ratios and tablet hardness can also affect the dissolution profile . The release rate is largely independent of pH and agitation, suggesting robust performance across different gastrointestinal conditions .
In Vitro–In Vivo Correlation
A strong correlation exists between in vitro drug release and in vivo absorption for metoprolol tartrate ER formulations, supporting the predictability of pharmacokinetic behavior based on dissolution testing . This relationship allows for reliable assessment of formulation performance and aids in the development of bioequivalent generic products 14.
Clinical Relevance of Pharmacokinetic Variability
While formulation-related differences in drug release can lead to measurable differences in pharmacokinetic parameters such as Cmax and area under the curve (AUC), these differences do not always translate into clinically significant changes in therapeutic effect, such as exercise-induced heart rate reduction . This suggests that the clinical impact of minor pharmacokinetic variability among ER formulations may be limited .
Conclusion
Metoprolol tartrate extended release tablets provide sustained drug release and prolonged plasma concentrations, with pharmacokinetics influenced by formulation variables and polymer content. The ER formulations are generally bioequivalent across brands, and in vitro dissolution testing reliably predicts in vivo absorption. While pharmacokinetic differences can occur due to formulation changes, these are not always clinically significant, supporting the use of ER tablets for consistent and effective blood pressure management 1234+4 MORE.
Sources and full results
Most relevant research papers on this topic